During the last session, Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares were 0.64 million, with the beta value of the company hitting -0.30. At the end
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares stood at 1.08 million during the last session, with the company’s beta value hitting -0.31. At the close of
During the last session, Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares were 0.38 million, with the beta value of the company hitting -0.03. At the end
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares stood at 1.01 million during the last session, with the company’s beta value hitting -0.13. At the close of
In the last trading session, 1.27 million Mineralys Therapeutics Inc (NASDAQ:MLYS) shares changed hands as the company’s beta touched 0.27. With the company’s per share
In the last trading session, 1.58 million Mineralys Therapeutics Inc (NASDAQ:MLYS) shares changed hands as the company’s beta touched -0.13. With the company’s per share
In last trading session, Mineralys Therapeutics Inc (NASDAQ:MLYS) saw 1.11 million shares changing hands with its beta currently measuring -0.38. Company’s recent per share price
Mineralys Therapeutics Inc (NASDAQ:MLYS) has a beta value of -0.19 and has seen 2.15 million shares traded in the last trading session. The company, currently
Mineralys Therapeutics Inc (NASDAQ:MLYS) has a beta value of 0.08 and has seen 1.69 million shares traded in the last trading session. The company, currently
During the last session, Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares were 1.04 million, with the beta value of the company hitting -0.08. At the end
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
